On December 2, Bradley Fluegel notified the Board of Directors of NeuroMetrix (NURO), of his decision to resign from the Board and as a member of the Board’s Audit Committee, effective as of December ...

Medical device maker NeuroMetrix has agreed to pay $3.7 million to settle federal allegations that it gave kickbacks to physicians, according to news releases from the U.S. Attorney’s Office and ...

WOBURN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NURO) today announced that over 2000 fibromyalgia patients have been prescribed Quell Fibromyalgia since its strategic commercial ...

Shares have lost half their value since this spring as a number of insurers have said they would restrict reimbursement for the company's nerve tests. But some investors are betting doctors who find ...

WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the diagnosis and treatment of neurological complications of diabetes announced that it will ...

WOBURN, Mass., April 28, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NURO) announced today that it plans to issue its 2023 first quarter financial results before the opening of the market on May 3, ...

Neurometrix Inc. (NASDAQ:NURO) shares flew higher Tuesday and Wednesday on continued momentum after the company announced its Quell device received Breakthrough Designation from the FDA for treating ...

WALTHAM, Mass.--(BUSINESS WIRE)--NeuroMetrix, Inc. (Nasdaq: NURO, NUROW) announced today that Synovation Medical Group will conduct an evaluation of Quell ® Wearable Pain Relief Technology™ in ...

WALTHAM, Mass., April 17, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) announced today that it plans to issue its 2019 first quarter financial results before the opening of the market on ...